POTELLIGENT® enables monoclonal antibodies to be manufactured in 100% fucose-free form, resulting in significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) and tumor cell-killing activity. BioWa, Inc., a member of the Kyowa Hakko Kirin Group, is the exclusive licensor of POTELLIGENT®.

We are applying POTELLIGENT® to our own and our partners’ antibody products under a non-exclusive license from BioWa.

POTELLIGENT® has been commercially validated by mogamulizumab (Poteligeo®), a non-fucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4), developed by Kyowa Hakko Kirin and approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.